Cladribine (DB00242): A Comprehensive Pharmacological and Clinical Monograph

I. Executive Summary

Cladribine is a synthetic purine nucleoside analogue that occupies a unique and dichotomous position in contemporary pharmacotherapy. It exists as two distinct therapeutic entities, defined by formulation and indication, each addressing a fundamentally different pathological process. As an intravenous infusion sold under brand names such as Leustatin, it functions as a potent antineoplastic agent for the treatment of hairy cell leukemia (HCL), a rare hematological malignancy.[1] In its oral tablet formulation, marketed as Mavenclad, it serves as a high-efficacy, short-course immune reconstitution therapy for adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting and active secondary progressive disease.[1]

The therapeutic utility of Cladribine in these disparate fields is rooted in a single, powerful mechanism of action: the selective induction of apoptosis in B and T lymphocytes.[2] As a prodrug, Cladribine is metabolically activated intracellularly to its cytotoxic triphosphate form. Its selectivity is not achieved through targeted binding to surface receptors, but rather by exploiting an intrinsic enzymatic imbalance within lymphocytes, which possess high levels of the activating kinase (deoxycytidine kinase) and low levels of the deactivating nucleotidase. This leads to the accumulation of the active metabolite, which disrupts DNA synthesis and repair, triggers cellular energy depletion, and initiates mitochondrial-mediated cell death.[1] This targeted depletion of lymphocytes underpins its efficacy in both B-cell malignancies and autoimmune demyelinating disease.

The development and regulatory history of Cladribine is a compelling narrative of evolving risk-benefit assessment. First approved in 1993 for HCL, its significant cytotoxic potential was deemed an acceptable risk for a life-threatening cancer.[2] Its subsequent journey toward an MS indication was far more challenging, marked by initial regulatory rejections due to concerns over long-term risks, particularly malignancy.[7] Only after extensive long-term clinical trial data demonstrated a durable efficacy that allowed for a short, intermittent dosing schedule—thereby limiting cumulative exposure—was the risk-benefit profile considered favorable for a specific subset of patients with highly active MS.[7] Consequently, the clinical application of Cladribine is governed by stringent safety protocols, including comprehensive patient screening, vaccination requirements, and diligent hematological monitoring, reflecting the delicate balance between its profound therapeutic effects and its significant, well-characterized risks.[10] This monograph provides an exhaustive analysis of Cladribine's chemical properties, its complex pharmacology, the pivotal clinical evidence supporting its dual indications, its comprehensive safety profile, and its notable developmental history.

II. Chemical Identity and Physicochemical Properties

The precise identification and characterization of a small molecule drug are foundational to understanding its pharmacological behavior. Cladribine is a well-defined chemical entity with a comprehensive set of identifiers and established physicochemical properties.

Systematic Identification

Cladribine is recognized across global chemical and pharmaceutical databases by a unique set of identifiers. Its Chemical Abstracts Service (CAS) Registry Number is 4291-63-8.[1] In pharmacological contexts, it is cataloged under DrugBank Accession Number DB00242 and PubChem Compound ID (CID) 20279.[1]

The compound is known by numerous synonyms, reflecting its history from chemical synthesis to clinical use. Its primary chemical name is 2-Chloro-2'-deoxyadenosine.[1] It is also commonly referred to by the abbreviation 2-CdA.[1] During its development, it was assigned code names such as RWJ-26251 and NSC 105014.[16] A comprehensive list of its identifiers and properties is provided in Table II.A.

Structural and Chemical Data

Cladribine is structurally a purine nucleoside analogue, specifically a chlorinated derivative of 2'-deoxyadenosine.[15] The molecular formula is

C10​H12​ClN5​O3​.[1] This composition corresponds to an average molecular weight of 285.69 g·mol−1 and a more precise monoisotopic mass of 285.062867 Da.[1]

The systematic IUPAC name for the molecule is (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol.[1] Its structure is unambiguously defined for computational and database purposes by standardized chemical notations:

• SMILES (Simplified Molecular Input Line Entry System): Clc1nc(c2ncn(c2n1)[C@@H]3O[C@@H]([C@@H](O)C3)CO)N [1]
• InChI (International Chemical Identifier): InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1 [1]
• InChIKey: PTOAARAWEBMLNO-KVQBGUIXSA-N [1]

As an organochlorine compound, the substitution of a chlorine atom for a hydrogen at the 2-position of the purine ring is a critical structural feature that confers resistance to enzymatic degradation, a key aspect of its mechanism of action.[15]

Physicochemical Characteristics

The physical and chemical properties of Cladribine influence its formulation, stability, and biological interactions. It is soluble in dimethyl sulfoxide (DMSO) up to a concentration of 100 mM.[13] The molecule's stability is pH-dependent; it is stable at neutral and slightly basic pH but undergoes significant decomposition via hydrolysis under acidic conditions.[21] This property is relevant for both its intravenous formulation and its passage through the gastrointestinal tract as an oral tablet. The ionization behavior is characterized by a single pKa of approximately 1.21.[21]

Computational chemistry provides further insight into its properties. The Topological Polar Surface Area (TPSA) is calculated to be 119.31 Ų, and the partition coefficient (LogP) is -0.2974, indicating a relatively polar molecule with limited lipophilicity, which is consistent with its reliance on nucleoside transporters for efficient cellular uptake.[22]

Table II.A: Summary of Cladribine Identifiers and Chemical Properties

Property	Value	Source(s)
Drug Name	Cladribine	2
DrugBank ID	DB00242	2
CAS Number	4291-63-8	1
Molecular Formula	C10​H12​ClN5​O3​	1
Average Molecular Weight	285.69 g·mol−1	1
Monoisotopic Mass	285.062867 Da	2
IUPAC Name	(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol	1
SMILES String	Clc1nc(c2ncn(c2n1)[C@@H]3O[C@@H]([C@@H](O)C3)CO)N	1
InChIKey	PTOAARAWEBMLNO-KVQBGUIXSA-N	1
Key Synonyms	2-CdA, 2-Chlorodeoxyadenosine, Leustatin, Mavenclad	1
Solubility	Soluble to 100 mM in DMSO	13

III. Comprehensive Pharmacology

The pharmacological profile of Cladribine is characterized by a highly selective mechanism of action that belies its structural simplicity. Its effects are a direct consequence of its ability to exploit the unique metabolic machinery of lymphocytes, leading to their depletion. The pharmacokinetics of the drug are heavily influenced by its formulation, resulting in two distinct clinical profiles for its oral and intravenous routes of administration.

A. Pharmacodynamics: Mechanism of Selective Lymphocyte Depletion

Cladribine's pharmacodynamic effects are centered on its ability to induce apoptosis in both dividing and quiescent lymphocytes and monocytes.[24] This is achieved through a multi-step process involving cellular uptake, metabolic activation, and the triggering of several parallel cell death pathways.

Prodrug Nature and Intracellular Activation

Cladribine in its administered form is an inactive prodrug that passively crosses the cell membrane and is also actively transported into cells via nucleoside transporter proteins.[2] Its journey to becoming a potent cytotoxic agent begins once it is inside the target cell. The first and rate-limiting step in its activation is phosphorylation to cladribine monophosphate (Cd-AMP) by the enzyme deoxycytidine kinase (DCK), with a contribution from mitochondrial deoxyguanosine kinase.[2] Cd-AMP is then sequentially phosphorylated by other cellular kinases to form cladribine diphosphate (Cd-ADP) and finally the active cytotoxic moiety, 2-chloro-2'-deoxy-β-D-adenosine triphosphate (Cd-ATP).[2]

The Basis of Selective Cytotoxicity

The remarkable selectivity of Cladribine for lymphocytes is not due to preferential uptake but rather to a critical imbalance in intracellular enzyme activities. Lymphocytes and monocytes are characterized by a high ratio of the activating enzyme, DCK, to the primary deactivating enzyme, cytoplasmic 5'-nucleotidase (5'-NT), which dephosphorylates and inactivates Cd-AMP.[1] This metabolic trap ensures that once Cladribine enters a lymphocyte, it is efficiently converted to its active form and accumulates to toxic intracellular concentrations.[1] Most other cell types possess a lower DCK/5'-NT ratio and are thus able to clear the drug before it reaches cytotoxic levels. Furthermore, the chlorine atom at the 2-position of the purine ring renders Cladribine resistant to degradation by adenosine deaminase (ADA), an enzyme that would otherwise inactivate its parent nucleoside, deoxyadenosine.[13] This resistance prevents premature breakdown and further contributes to its intracellular accumulation and prolonged effect.

This mechanism represents a unique form of targeted therapy. Unlike monoclonal antibodies, which are engineered to bind to specific cell surface proteins, Cladribine is a simple molecule that achieves its specificity by hijacking the inherent metabolic vulnerabilities of its target cells. Its efficacy is a direct function of the target's own internal enzymatic machinery, making it a "passive" smart drug whose lethality is unlocked only within the intended cellular environment. This explains both its profound and long-lasting effects on lymphocytes and the potential for dose-dependent toxicity in other tissues if systemic concentrations become excessively high, as seen with high-dose intravenous regimens.[2]

Multi-Pronged Cytotoxic Mechanisms

Once accumulated, Cd-ATP induces apoptosis through at least three distinct but complementary mechanisms, ensuring robust elimination of the target cell.

1. DNA Synthesis Inhibition and Repair Disruption: As a structural analogue of deoxyadenosine triphosphate (dATP), Cd-ATP is erroneously incorporated into DNA strands by DNA polymerases during both replication and repair.[1] This incorporation leads to the termination of DNA chain elongation and the accumulation of single- and double-strand breaks. The presence of Cd-ATP also directly inhibits key enzymes involved in DNA metabolism, such as ribonucleotide reductase, further starving the cell of the necessary building blocks for DNA synthesis and repair.[2] This direct assault on genomic integrity is a primary driver of its cytotoxic effect.
2. Energy Depletion via PARP Activation: The extensive DNA damage caused by Cd-ATP triggers a strong cellular stress response, including the hyperactivation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP).[2] PARP is a critical DNA repair enzyme that consumes nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP) as substrates. Its over-activation in response to widespread DNA damage rapidly depletes the cell's energy stores, leading to a metabolic crisis and subsequent programmed cell death.[2]
3. Mitochondrial-Mediated Apoptosis: Cladribine can also initiate apoptosis directly at the level of the mitochondria. It has been shown to alter the mitochondrial transmembrane potential, causing the release of pro-apoptotic factors such as cytochrome c and apoptosis-inducing factor (AIF) into the cytosol.[2] This event triggers both caspase-dependent and caspase-independent apoptotic cascades, providing a redundant and powerful mechanism to ensure cell death even in non-dividing cells.

Differential Effects on Lymphocyte Subsets

While Cladribine targets both B and T lymphocytes, clinical data, particularly from MS trials, indicate a more profound and sustained effect on B cells. Studies have shown that Cladribine treatment leads to a selective depletion of approximately 80% of peripheral B cells, compared to a more moderate depletion of 40–45% of CD4+ T cells and 15–30% of CD8+ T cells.[1] Within the B-cell population, memory B cells appear to be particularly susceptible and are depleted for a prolonged period, whereas naive B cells repopulate more quickly.[1] This differential impact is thought to be central to its therapeutic effect in MS, positioning it as an "immune reconstitution therapy" that reshapes the adaptive immune system rather than simply suppressing it broadly.

B. Pharmacokinetics: A Tale of Two Formulations

The clinical application of Cladribine is fundamentally shaped by its pharmacokinetic profile, which differs significantly between its oral and intravenous formulations. These differences in absorption, distribution, and elimination dictate the dosing strategies and therapeutic windows for its distinct indications in MS and HCL.

A critical aspect of Cladribine's pharmacology is the apparent disconnect between its plasma pharmacokinetics and its cellular pharmacodynamics. The plasma half-life of the parent drug is relatively short, which might suggest a need for continuous or frequent dosing.[2] However, the therapeutic strategy, especially for MS, involves very short, intermittent courses of treatment separated by a year.[27] This is possible because the true driver of efficacy is not the concentration of Cladribine in the plasma, but the concentration and persistence of its active metabolite, Cd-ATP,

inside the target lymphocytes. The intracellular half-life of Cd-ATP is substantially longer (approximately 10 hours) than the plasma half-life of the parent drug.[2] Because lymphocytes are metabolically trapped with high levels of this active metabolite, a short burst of systemic exposure is sufficient to "load" the target cells with enough cytotoxic agent to ensure their depletion over the subsequent weeks and months. This principle of long intracellular retention is the pharmacokinetic foundation of the immune reconstitution therapy paradigm for Mavenclad in MS.

Absorption

• Oral (Mavenclad): Following oral administration, Cladribine has a bioavailability of approximately 40% (range 37–51%).[1] Under fasted conditions, it is absorbed rapidly, with a median time to maximum plasma concentration (Tmax) of 0.5 hours.[2] The administration with a high-fat meal reduces the maximum concentration (Cmax) by about 29% and delays the Tmax to 1.5 hours; however, the total drug exposure (AUC) remains unchanged. This effect is not considered clinically significant, and Mavenclad can therefore be administered with or without food.[2]
• Intravenous (Leustatin): As an intravenous drug, its bioavailability is 100% by definition.[1] For HCL, it is typically administered as a continuous infusion over seven days, which achieves a mean steady-state plasma concentration of approximately 5.7 ng/mL.[2]

Distribution

Cladribine exhibits extensive distribution throughout the body. The apparent volume of distribution is large, estimated at approximately 9 L/kg for the IV formulation and 480–490 L for the oral formulation, indicating significant penetration into body tissues beyond the plasma compartment.[2] A crucial feature for its use in MS is its ability to cross the blood-brain barrier and penetrate the cerebrospinal fluid (CSF), where its concentration reaches about 25% of that in the plasma.[2] Plasma protein binding is low, at approximately 20–25%, and is independent of drug concentration.[1]

Metabolism

The primary metabolic pathway for Cladribine is its intracellular phosphorylation to the active Cd-ATP within target lymphocytes, as detailed previously.[2] It is important to note that hepatic metabolism via cytochrome P450 enzymes is negligible. Instead, metabolism occurs extensively within whole blood and target tissues where the necessary kinases are present.[2]

Elimination

The elimination half-life and clearance pathways differ between the two formulations.

• Oral (Mavenclad): The terminal elimination half-life following oral administration is approximately one day.[2] Renal excretion is a significant route of elimination, with about 28.5% of an oral dose excreted unchanged in the urine. The renal clearance rate exceeds the glomerular filtration rate, suggesting that active renal tubular secretion contributes to its elimination.[2]
• Intravenous (Leustatin): After IV administration, the plasma concentration declines multi-exponentially with a shorter average half-life of 5.4 to 6.7 hours.[2] Approximately 18% of an infused dose is recovered unchanged in the urine.[2]

Table III.B: Comparative Pharmacokinetic Parameters of Oral vs. Intravenous Cladribine

Parameter	Oral Cladribine (Mavenclad)	Intravenous Cladribine (Leustatin)	Source(s)
Bioavailability	~40% (37-51%)	100%	1
Tmax	~0.5 hours (fasted)	Not Applicable (infusion)	2
Food Effect	Cmax decreased ~29%, Tmax delayed; AUC unchanged (not clinically significant)	Not Applicable	2
Plasma Half-Life	~1 day (terminal)	~5.4 - 6.7 hours	2
Intracellular Half-Life (Cd-ATP)	~10 hours	~10 hours	2
Protein Binding	~20%	~20%	1
Volume of Distribution	480 - 490 L	~9 L/kg	2
CSF Penetration	Yes (~25% of plasma concentration)	Yes (~25% of plasma concentration)	2
Primary Route of Elimination	Renal (~28.5% unchanged) and non-renal clearance	Renal (~18% unchanged) and non-renal clearance	2

IV. Clinical Efficacy and Therapeutic Applications

Cladribine's clinical utility is sharply divided into two distinct areas, each supported by a robust body of evidence from pivotal clinical trials. Its oral formulation, Mavenclad, is an established high-efficacy therapy for relapsing MS, while its intravenous formulation, Leustatin, remains a cornerstone treatment for HCL.

A. Indication 1: Relapsing Multiple Sclerosis (Oral Cladribine - Mavenclad)

In the context of MS, Cladribine is not a chronic immunosuppressant but an immune reconstitution therapy, administered in short courses to induce long-term remission of disease activity.

Regulatory Status and Indication Specifics

The approved indications for oral Cladribine reflect a careful balance between its demonstrated efficacy and its significant safety profile.

• U.S. Food and Drug Administration (FDA): Mavenclad is indicated for the treatment of relapsing forms of MS in adults, which includes relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).[10] Critically, the FDA label includes a limitation of use: "Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS".[2] Furthermore, it is explicitly not recommended for patients with Clinically Isolated Syndrome (CIS), the earliest presentation of the disease.[29]
• European Medicines Agency (EMA): In Europe, Mavenclad is approved for the treatment of adult patients with "highly active" relapsing MS, a designation defined by specific clinical or imaging features, such as having relapses while on another disease-modifying therapy (DMT) or having a high burden of inflammatory lesions on MRI.[1]

This distinction between indications highlights a crucial aspect of Cladribine's regulatory history. The ORACLE-MS trial conclusively demonstrated that Cladribine is highly effective at delaying the conversion from CIS to clinically definite MS.[34] Logically, this would support an indication for early treatment at the CIS stage. However, regulators, particularly the FDA, determined that the risk-benefit profile was unfavorable for this population. Since a subset of CIS patients may not progress to active MS for many years, exposing the entire group to a drug with known long-term risks, such as malignancy, was deemed inappropriate.[7] This decision exemplifies how a drug's safety profile can override proven efficacy for a specific indication, leading to a more restricted label that reserves its use for patients with more established and active disease, where the benefits more clearly outweigh the risks.

Dosage, Administration, and Patient Handling

The dosing regimen for Mavenclad is unique among MS therapies. The total recommended cumulative dose is 3.5 mg/kg of body weight, administered over two years.[1]

• Treatment Courses: The total dose is divided into two annual treatment courses of 1.75 mg/kg each.[33]
• Treatment Cycles: Each annual course is further divided into two short treatment cycles (or weeks), administered approximately one month apart (at the beginning of month 1 and month 2 of each treatment year).[27]
• Daily Dosing: During each 4- or 5-day cycle, the patient takes one or two 10 mg tablets once daily, with the exact number determined by their body weight.[37]
• Treatment-Free Period: A key feature of the regimen is that after the completion of the two annual courses, no further Cladribine treatment is administered in years 3 and 4.[27]

As a cytotoxic drug, strict handling procedures are required. Tablets must be swallowed whole with water and should not be crushed or chewed. They can be taken with or without food but must be separated from any other oral medications by at least three hours. Patients and caregivers must handle the tablets with dry hands and wash their hands and any exposed surfaces thoroughly after contact.[12]

Pivotal Clinical Trial Evidence

The approval of Mavenclad for MS is supported by a comprehensive clinical development program, most notably the CLARITY, CLARITY Extension, and ORACLE-MS trials.

• CLARITY (NCT00213135): This pivotal, 96-week, placebo-controlled Phase 3 trial enrolled 1,326 patients with RRMS. The study demonstrated robust efficacy for Cladribine. Compared to placebo, the 3.5 mg/kg cumulative dose resulted in a 58% relative reduction in the annualized relapse rate (ARR) (0.14 vs. 0.33 for placebo).[7] The trial also met key secondary endpoints, showing a 33% reduction in the risk of 3-month sustained disability progression and significant reductions in all primary MRI measures, including the number of gadolinium-enhancing (T1-Gd+) lesions, active T2 lesions, and combined unique lesions.[7]
• CLARITY Extension (NCT00641537): This trial was designed to evaluate the long-term safety and efficacy of Cladribine. Patients who completed CLARITY were re-randomized to receive either another two years of Cladribine (3.5 mg/kg) or placebo. The most significant finding was the durability of the initial treatment effect. Patients who received Cladribine for two years followed by two years of placebo maintained a low ARR and a high proportion of relapse-free status (75.6%), similar to those who received four continuous years of treatment (81.2% relapse-free).[41] While four years of treatment offered a slight incremental benefit, it was associated with higher rates of grade 3-4 lymphopenia.[43] These results provided the core evidence for the short-course immune reconstitution therapy concept, demonstrating that the benefits of the initial two courses are sustained for at least four years in the majority of patients.[41]
• ORACLE-MS (NCT00725985): This Phase 3 trial evaluated Cladribine in 616 patients presenting with a first clinical demyelinating event (CIS). Both the 3.5 mg/kg and 5.25 mg/kg doses of Cladribine significantly delayed the time to conversion to clinically definite MS (CDMS) by 67% and 62%, respectively, compared with placebo.[34] The study also demonstrated a rapid onset of action, with beneficial effects on active MRI lesions evident as early as 13 weeks after the first treatment course.[45]

Long-term Efficacy and Registry Data

The CLASSIC-MS (NCT03961204) study provided long-term follow-up data on patients from the original CLARITY and ORACLE-MS trials. At a median follow-up of 10.9 years after their last study dose, the findings confirmed the sustained long-term benefits of Cladribine on mobility and disability. Remarkably, 55.8% of patients who had been exposed to at least one course of Cladribine in the parent trials had not required any subsequent disease-modifying therapy.[46] This provides powerful real-world evidence for the durable, long-term efficacy achievable with this short-course treatment.

Table IV.A: Summary of Key Efficacy Endpoints from Pivotal MS Clinical Trials

Endpoint	CLARITY (3.5 mg/kg vs. Placebo)	CLARITY Extension (2-yr vs. 4-yr treatment)	ORACLE-MS (3.5 mg/kg vs. Placebo)
Annualized Relapse Rate (ARR)	0.14 vs. 0.33 (58% reduction) 7	ARR remained low in both groups (0.15 vs. 0.10) 41	Not a primary endpoint; focused on conversion.
Risk of 3-Month Disability Progression	33% risk reduction (HR 0.67) 7	No significant difference between groups 41	74% risk reduction for next attack or EDSS worsening in patients meeting MS criteria at baseline 44
Reduction in T1 Gd+ Lesions	86% relative reduction 50	Efficacy maintained in both groups 43	Significant reduction evident by Week 13 45
Reduction in Active T2 Lesions	73% relative reduction 50	Efficacy maintained in both groups 43	Significant reduction evident by Week 13 45
Time to Conversion to CDMS	Not Applicable	Not Applicable	67% risk reduction (HR 0.33) 35

B. Indication 2: Hairy Cell Leukemia (Intravenous Cladribine - Leustatin)

As an antineoplastic agent, intravenous Cladribine has been a highly effective therapy for HCL for decades, capable of inducing deep and durable remissions with a single course of treatment.

Regulatory Status and Indication Specifics

Leustatin was first approved by the FDA in 1993 and is indicated for the treatment of active Hairy Cell Leukemia, which is defined by the presence of clinically significant anemia, neutropenia, thrombocytopenia, or other disease-related symptoms.[2] It is established as both a first-line therapy for newly diagnosed patients and a second-line therapy for those who have relapsed or are refractory to other treatments.[1]

Dosage, Administration, and Infusion Preparation

The standard and recommended regimen for HCL is a single course of Cladribine administered at a dose of 0.09 mg/kg/day by continuous intravenous infusion for 7 consecutive days.[11] Deviations from this dosage are not advised.

The preparation of the infusion requires strict aseptic technique. The calculated daily dose must be diluted in 500 mL of 0.9% Sodium Chloride Injection, USP. The use of 5% Dextrose as a diluent is not recommended due to increased drug degradation.30 The solution should be passed through a sterile 0.22µm filter during preparation.30 A 7-day infusion can also be prepared using Bacteriostatic 0.9% Sodium Chloride Injection, which allows for administration via a portable infusion pump.30

Foundational Clinical Trial Evidence

The approval of Leustatin for HCL was based on the results of two pivotal, single-center, open-label studies conducted at the Scripps Clinic and Research Foundation and the M.D. Anderson Cancer Center.[11] These trials demonstrated high rates of durable remission.

• Response Rates: In the combined analysis of evaluable patients (N=106), the complete response (CR) rate was 66%, and the overall response rate (ORR), which included partial responses, was 88%.[11]
• Efficacy in Different Settings: The drug proved effective in both treatment-naive patients (92% ORR) and in patients who had been previously treated with agents like interferon-alpha or splenectomy (84% ORR).[11]
• Hematologic Recovery: Treatment led to the normalization of peripheral blood counts in the vast majority of patients. The median time to recovery was approximately 2 weeks for platelets, 5 weeks for absolute neutrophil count, and 8 weeks for hemoglobin.[11]

C. Investigational and Off-Label Uses

Beyond its two primary approved indications, Cladribine's potent lymphocytotoxic properties have led to its investigation and use in a variety of other conditions. These include other B-cell malignancies such as B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma, as well as cutaneous T-cell lymphoma.[1] It has also been used, often in combination with other cytotoxic agents, to treat various rare histiocytic disorders like Langerhans cell histiocytosis and Erdheim–Chester disease.[1]

V. Safety Profile, Toxicology, and Risk Management

The potent mechanism of action that underlies Cladribine's efficacy is also the source of its significant safety and toxicity concerns. A thorough understanding of its adverse event profile and the implementation of a comprehensive risk management strategy are paramount for its safe use in any clinical setting. The safety profiles for the oral MS formulation (Mavenclad) and the intravenous HCL formulation (Leustatin) share common themes related to myelosuppression and infection risk, but also have distinct features, including boxed warnings tailored to their respective indications and patient populations.

A. Boxed Warnings and Contraindications

The most severe risks associated with Cladribine are highlighted in boxed warnings on the prescribing information for both formulations.

Mavenclad (Oral)

The boxed warnings for the oral formulation focus on long-term and systemic risks relevant to a chronic autoimmune disease population.

• Malignancy: Treatment with Mavenclad may increase the risk of malignancy. It is therefore contraindicated in patients with a current malignancy. For patients with a prior history of cancer or those at increased risk, a careful individual risk-benefit assessment is required before initiating therapy.[10]
• Teratogenicity: Cladribine can cause fetal harm. It is contraindicated for use in pregnant women and in both women and men of reproductive potential who do not plan to use effective contraception. Contraception is required during treatment and for at least 6 months after the last dose in each annual treatment course.[10]

In addition to these, Mavenclad is contraindicated in patients with active HIV infection, active chronic infections such as tuberculosis or hepatitis, a history of hypersensitivity to Cladribine, and in women who intend to breastfeed during treatment and for 10 days after the last dose.[10]

Leustatin (IV)

The boxed warnings for the intravenous formulation emphasize the acute, dose-dependent toxicities associated with its use as an antineoplastic agent.

• Severe Myelosuppression: Administration of Leustatin should be supervised by a physician experienced in antineoplastic therapy. Suppression of bone marrow function is an expected and common consequence, though it is usually reversible and dose-dependent.[11]
• Neurotoxicity and Nephrotoxicity: Serious and irreversible neurological toxicity (e.g., paraparesis, quadriparesis) and acute nephrotoxicity have been reported, primarily in patients who received high doses (4 to 9 times the recommended dose for HCL). While dose-related, severe neurotoxicity has been reported rarely even at standard doses.[11]

The only absolute contraindication for Leustatin is a known hypersensitivity to Cladribine or any of its components.[55]

B. Adverse Events and Organ System Toxicity

The adverse event profile of Cladribine is extensive and directly linked to its mechanism of action.

Lymphopenia and Hematologic Toxicity

Lymphopenia is the most common and pharmacologically expected adverse event, occurring in the vast majority of patients treated with either formulation.[56] For Mavenclad, lymphocyte counts typically reach their nadir 2 to 3 months after the start of each treatment course.[4] While most cases are Grade 1-3, severe Grade 4 lymphopenia (<200 cells/µL) can occur.[1] For Leustatin, severe myelosuppression is frequent, with high rates of neutropenia (~70%), anemia, and thrombocytopenia observed in the first month of therapy.[3] Pancytopenia and bone marrow hypoplasia have also been reported.[56]

Infections

The primary clinical consequence of Cladribine-induced lymphopenia is an increased risk of infections. In MS clinical trials, infections occurred in 49% of Mavenclad-treated patients compared to 44% of placebo patients.[10]

• Herpes Zoster (Shingles): There is a significantly increased risk of herpes zoster, particularly during periods of severe lymphopenia. In MS trials, the incidence was 2.0% with Mavenclad versus 0.2% with placebo.[1]
• Opportunistic Infections: Serious and sometimes fatal opportunistic infections can occur. The clinical development program for Cladribine reported fatal cases of tuberculosis and fulminant hepatitis B, highlighting the risk of reactivating latent infections.[10]
• Progressive Multifocal Leukoencephalopathy (PML): PML is a rare, severe brain infection caused by the John Cunningham (JC) virus. While no cases have been reported in MS patients treated with Mavenclad, PML has been observed in patients treated with parenteral Cladribine for oncologic indications. Given the profound and prolonged lymphopenia it induces, PML remains a theoretical risk that requires clinical vigilance.[10]

Malignancy

The risk of malignancy is a major long-term concern, particularly for the oral formulation used in MS, and is the subject of a boxed warning. Cladribine interferes with DNA synthesis and repair, giving it mutagenic potential.[25] In controlled clinical studies, malignancies occurred more frequently in Cladribine-treated patients than in those receiving placebo.[24] The risk may be further increased if additional treatment is administered within two years of completing the standard two-course regimen.[36]

Organ-Specific Toxicities

• Liver Injury: Cases of clinically significant liver injury, characterized by elevated serum transaminases, have been reported in a small percentage of patients (0.3% in MS trials).[10]
• Cardiac Failure: Rare but serious cases of life-threatening acute cardiac failure, sometimes associated with myocarditis, have been observed with both oral and parenteral Cladribine.[10]
• Neurologic Toxicity: As noted in the boxed warning, severe neurotoxicity is primarily a risk with high-dose intravenous use. However, rare cases of peripheral neuropathy and other neurologic events have been reported with standard doses.[11] Seizures have also occurred in patients treated with Mavenclad.[31]
• Hypersensitivity: Hypersensitivity reactions can occur. Rare but severe skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are identified risks of parenteral Cladribine.[52]

C. Risk Mitigation and Monitoring

Due to its significant safety profile, the use of Cladribine requires a structured and comprehensive risk management plan.

• Pre-Treatment Screening: Before initiating therapy, all patients must undergo extensive screening. This includes excluding active infections such as HIV, active or latent tuberculosis (via skin test or IGRA), and hepatitis B and C.[1] For MS patients, a baseline MRI within the preceding 3 months is required to establish a reference for monitoring for PML.[10] Pregnancy must also be excluded in females of reproductive potential.[56]
• Vaccination: Patients who are antibody-negative for the varicella zoster virus (VZV) should be vaccinated prior to starting Cladribine. The administration of live or live-attenuated vaccines is contraindicated for 4 to 6 weeks before initiating therapy and should be avoided during and after treatment until lymphocyte counts have recovered to safe levels.[1]
• Monitoring During and After Treatment:
• Hematologic: A complete blood count (CBC) with differential, including absolute lymphocyte count, is mandatory. For Mavenclad, this is required before each annual course, at 2 and 6 months after the start of each course, and as clinically indicated thereafter.[10] For Leustatin, frequent monitoring of peripheral blood counts is essential, particularly during the first 4 to 8 weeks post-treatment.[5]
• Infection Prophylaxis and Monitoring: Patients with severe lymphopenia (absolute lymphocyte count <200 cells/µL) should receive anti-herpes prophylaxis.[10] All patients should be monitored for signs and symptoms of infection.
• Organ Function: Periodic assessment of renal and hepatic function is recommended, especially in patients with underlying dysfunction.[5] For Mavenclad, liver function tests are required before each treatment course.[33]
• Special Considerations:
• Blood Transfusions: To mitigate the rare risk of transfusion-associated graft-versus-host disease, it is recommended that any cellular blood components required by a patient be irradiated prior to transfusion.[10]
• Special Populations: Caution is advised when treating elderly patients. Cladribine is not recommended for use in patients with moderate to severe renal or hepatic impairment, or in pediatric patients.[31]

Table V.B: Comparative Adverse Event Profiles for Mavenclad (MS) and Leustatin (HCL)

Adverse Event (System Organ Class)	Mavenclad (MS) Incidence (%)	Leustatin (HCL) Incidence (%)	Source(s)
Blood/Lymphatic
Lymphopenia	24	Very Common*	56
Febrile Neutropenia	-	8	11
Infections
Upper Respiratory Tract Infection	38	-	56
Herpes Zoster	2	-	61
Nervous System
Headache	25	14	11
Dizziness	-	6	11
Gastrointestinal
Nausea	10	22	56
Vomiting	-	9	64
Skin Disorders
Rash	-	16	64
Alopecia	3	Rare	56
General Disorders
Fever	5	33	56
Fatigue	-	31	64
Back Pain	8	-	56
Administration Site Reaction	Not Applicable	11	11
*Incidence not quantified but described as a very common event in HCL patients.

VI. Drug and Food Interactions

The safe administration of Cladribine requires careful consideration of potential interactions with other medications. These interactions can be pharmacodynamic, involving additive effects on the immune or hematologic systems, or pharmacokinetic, involving alterations in the drug's absorption, distribution, or elimination.

Pharmacodynamic Interactions

• Immunosuppressive and Myelosuppressive Drugs: The most significant pharmacodynamic interactions involve other drugs that suppress the immune system or bone marrow. Concomitant use of Cladribine with other potent immunosuppressive or myelosuppressive drugs (e.g., cyclosporine, azathioprine, methotrexate) is generally not recommended. Such combinations can lead to additive effects, increasing the risk of profound and prolonged lymphopenia, neutropenia, and opportunistic infections.[5] Co-administration with certain other MS DMTs, such as interferon-beta, may also increase the risk of lymphopenia and is not recommended.[59] However, acute, short-term courses of corticosteroids can be administered if necessary.[10]
• Live Vaccines: The administration of live or live-attenuated vaccines is contraindicated in patients recently treated with or currently receiving Cladribine. Due to the drug-induced immunosuppression, there is a significant risk that the vaccine could cause a disseminated, active infection.[31] Vaccinations with these agents should be completed at least 4-6 weeks prior to initiating Cladribine therapy.[56]

Pharmacokinetic Interactions

Pharmacokinetic interactions are particularly relevant for the oral formulation, Mavenclad, and primarily involve drug transporters and intracellular metabolic pathways.

• Transporter-Mediated Interactions: Cladribine is a substrate for several key drug transport proteins, including breast cancer resistance protein (BCRP), equilibrative nucleoside transporter 1 (ENT1), and concentrative nucleoside transporter 3 (CNT3).[23]
• Inhibitors: Co-administration with potent inhibitors of these transporters can increase the plasma concentration and intracellular exposure of Cladribine, potentially increasing toxicity. Therefore, concomitant use of potent BCRP, ENT1, or CNT3 inhibitors (e.g., ritonavir, eltrombopag, cyclosporine, nifedipine) should be avoided during the 4-5 day oral treatment cycles.[23]
• Inducers: Conversely, potent inducers of BCRP or P-glycoprotein (P-gp) transporters, such as rifampicin, corticosteroids, or St. John's Wort, may decrease Cladribine exposure, potentially reducing its efficacy.[61]
• Interference with Intracellular Activation: The therapeutic effect of Cladribine depends on its intracellular phosphorylation to Cd-ATP. It is theoretically possible that other drugs requiring intracellular phosphorylation to become active, such as certain antiviral and antiretroviral nucleoside analogues (e.g., lamivudine, zidovudine, ribavirin), could compete for the same kinases, thereby interfering with Cladribine's activation. Concomitant use of these agents should be avoided.[36]
• Drug-Excipient Interaction: The Mavenclad tablet formulation contains hydroxypropyl betadex, a solubilizing agent. This excipient can form complexes with other orally administered drugs, potentially increasing their bioavailability, especially for poorly soluble compounds. To mitigate this risk, it is a strict requirement that the administration of Mavenclad be separated from any other oral medication by at least 3 hours.[12]

Drug-Food Interactions

There are no clinically significant drug-food interactions for Cladribine. While the administration of oral Cladribine (Mavenclad) with a high-fat meal can slightly decrease the rate of absorption (lower Cmax, delayed Tmax), it does not affect the overall extent of absorption (AUC).[2] Therefore, Mavenclad can be taken with or without food, simplifying the dosing regimen for patients.[29]

Table VI.A: Major Drug-Drug Interactions and Management Recommendations

Interacting Drug/Class	Potential Effect	Clinical Recommendation	Mechanism
Immunosuppressants / Myelosuppressants (e.g., cyclosporine, methotrexate, azathioprine, interferon-beta)	Additive immunosuppression, increased risk of infection and severe lymphopenia.	Concomitant use is not recommended.	Pharmacodynamic Synergism
Hematotoxic Drugs	Additive effects on hematological profiles (e.g., neutropenia, thrombocytopenia).	Monitor patients for additive effects on the hematological profile.	Pharmacodynamic Synergism
Live or Live-Attenuated Vaccines (e.g., MMR, Varicella, Yellow Fever)	Risk of inducing disseminated vaccine-related infection.	Contraindicated. Administer at least 4-6 weeks prior to starting Cladribine.	Pharmacodynamic
Potent BCRP, ENT1, CNT3 Inhibitors (e.g., ritonavir, eltrombopag, cyclosporine)	Increased bioavailability and intracellular concentration of Cladribine, leading to increased toxicity.	Avoid concomitant use during the 4-5 day oral treatment cycles.	Pharmacokinetic (Inhibition of Influx/Efflux Transporters)
Potent BCRP or P-gp Inducers (e.g., rifampicin, St. John's Wort, corticosteroids)	Decreased Cladribine exposure, potentially reducing efficacy.	Consider potential for decreased efficacy.	Pharmacokinetic (Induction of Efflux Transporters)
Antiviral/Antiretroviral Nucleoside Analogues (e.g., lamivudine, zidovudine)	Potential interference with the intracellular phosphorylation (activation) of Cladribine.	Avoid concomitant use.	Pharmacokinetic (Competition for Activating Kinases)
All Other Oral Medications	Increased bioavailability of the other drug due to complex formation with hydroxypropyl betadex excipient.	Separate administration by at least 3 hours.	Pharmaceutical Interaction (Excipient-based)

VII. Developmental History and Future Directions

The trajectory of Cladribine from its synthesis to its current dual role in oncology and neurology is a remarkable case study in drug development, repurposing, and the evolving nature of risk-benefit assessment in medicine. Its history is defined by two distinct and challenging regulatory pathways, and its future continues to expand into new therapeutic areas.

A. Developmental and Regulatory History: A Tale of Two Approvals

Origins and HCL Approval

Cladribine (2-chlorodeoxyadenosine) was first synthesized in the 1970s.[26] Its development was inspired by clinical observations of children with adenosine deaminase (ADA) deficiency, a genetic disorder that leads to the accumulation of toxic deoxyadenosine nucleotides specifically in lymphocytes, causing severe immunodeficiency.[26] Researchers hypothesized that a synthetic nucleoside analogue resistant to ADA could mimic this effect and serve as a targeted therapy for lymphoproliferative diseases.

In the 1980s, researchers at the Scripps Institute, notably Drs. Ernest Beutler and Dennis Carson, tested Cladribine and discovered its profound efficacy in treating hairy cell leukemia (HCL), a previously intractable B-cell malignancy.[8] The drug was capable of inducing long-lasting remissions with a single course of treatment. Due to the rarity of HCL, it was considered an orphan disease, and there was little initial commercial interest from pharmaceutical companies. For a time, the Scripps lab synthesized and supplied the drug for clinical use.[8] In 1991, Scripps partnered with Johnson & Johnson to commercialize the intravenous formulation. Following a rapid development process, the U.S. FDA granted approval for Leustatin (cladribine) Injection in 1993 for the treatment of HCL, an indication for which it remains a standard of care.[1]

The Long Road to MS Approval

The journey to an MS indication was significantly more arduous. Based on its known immunosuppressive effects on lymphocytes, which are central to the pathogenesis of MS, clinical trials exploring its utility in the disease began in the mid-1990s.[8] An oral formulation was developed to improve convenience for a chronic condition.[8] The pivotal Phase 3 CLARITY trial demonstrated clear and robust efficacy in reducing relapse rates and disability progression in patients with relapsing-remitting MS.[7]

Despite these positive efficacy data, the initial marketing applications submitted to the EMA and FDA around 2009-2010 were rejected.[1] Regulators raised significant concerns about the drug's long-term safety profile, particularly an observed imbalance in malignancies in the clinical trials. The risk-benefit assessment was deemed unfavorable for a chronic, non-fatal condition like MS, especially with other approved therapies available.[1]

This regulatory setback prompted the sponsoring company, Merck KGaA, to conduct further long-term studies, including the CLARITY Extension trial. This trial was crucial as it demonstrated that the clinical benefits of the initial two-year treatment course were durable for at least four years, even without continuous therapy.[42] This finding was transformative, as it supported a short-course treatment paradigm that could limit cumulative drug exposure and, by extension, potentially mitigate long-term risks. With this new body of long-term safety and efficacy data, the risk-benefit equation shifted. The EMA granted approval for Mavenclad in 2017 for highly active relapsing MS, followed by FDA approval in 2019 for relapsing forms of MS in patients who have had an inadequate response to or cannot tolerate other therapies.[1] This history illustrates how the perception of a drug's risk profile can evolve over time with the accumulation of robust, long-term data, allowing a drug initially deemed too risky for a chronic condition to find a well-defined and valuable place in the therapeutic armamentarium.

B. Current and Future Research Landscape

Research into Cladribine continues to be active, exploring its use in new combinations, for new indications, and seeking to optimize its place in treatment algorithms.

Ongoing Clinical Trials

The current clinical trial landscape reflects a broad interest in leveraging Cladribine's mechanism of action.

• Hematologic Malignancies: A significant number of active trials are investigating Cladribine in combination regimens for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). These studies often pair Cladribine with other agents like the BCL-2 inhibitor Venetoclax and standard chemotherapy agents such as Cytarabine and Azacitidine, aiming to improve remission rates in high-risk and relapsed/refractory patient populations.[71] In HCL, trials continue to explore the combination of Cladribine with the anti-CD20 monoclonal antibody Rituximab to deepen responses and eliminate minimal residual disease.[71]
• Neurology and Immunology: The therapeutic potential of Cladribine is being explored beyond MS. A global Phase III trial, MyClad (NCT06463587), has recently been initiated to evaluate the efficacy and safety of oral Cladribine for the treatment of generalized Myasthenia Gravis (gMG), a chronic autoimmune neuromuscular disorder.[75] Success in this trial could establish Cladribine as the first short-course oral therapy for gMG. In MS, ongoing Phase 4 studies like CLADRINA (NCT04178005) are investigating the safety and efficacy of transitioning patients from other high-efficacy therapies, such as natalizumab, to Cladribine, which is a critical question in real-world clinical practice.[76]

Future Applications and Perspectives

The unique profile of Cladribine as a short-course oral immune reconstitution therapy positions it as a potential model for treating other autoimmune diseases. Its ability to induce a durable "reset" of the adaptive immune system without the need for continuous immunosuppression is a highly attractive therapeutic concept.

Future research will likely focus on identifying biomarkers that can predict both therapeutic response and the risk of adverse events. Such biomarkers could help personalize treatment, allowing clinicians to identify which MS patients are most likely to benefit from early high-efficacy treatment with Cladribine and which are at higher risk for complications like severe lymphopenia or secondary autoimmunity.[77] Furthermore, as long-term real-world safety and efficacy data continue to accumulate, the precise role of Cladribine in the MS treatment algorithm will be further refined. Cost-effectiveness analyses also suggest that its unique dosing schedule may offer substantial cost savings compared to other high-efficacy DMTs, which could influence its positioning in healthcare systems globally.[78]

VIII. Conclusion and Expert Synthesis

Cladribine (DB00242) stands as a testament to the enduring potential of rational drug design and the complex, evolving nature of therapeutic risk assessment. It is a molecule of profound dualities: a structurally simple purine analogue that functions as both a potent cytotoxic antineoplastic agent and a sophisticated, selective immune reconstitution therapy. Its clinical applications in hairy cell leukemia and relapsing multiple sclerosis, while pathologically distinct, are unified by a common pharmacodynamic principle—the targeted elimination of lymphocytes by exploiting their intrinsic metabolic vulnerabilities.

The success of Cladribine as Leustatin in HCL is rooted in its ability to induce high rates of durable remission with a single, intensive course of intravenous therapy. For this rare and aggressive malignancy, its potent myelosuppressive effects are a well-understood and acceptable component of the treatment paradigm. In contrast, the journey of oral Cladribine as Mavenclad in MS has been a lesson in nuance and perseverance. Its approval was contingent upon the demonstration of not just efficacy, but a durable efficacy that permitted a unique, short-course dosing regimen. This paradigm fundamentally alters the risk-benefit calculation, offering patients long-term disease control without continuous immunosuppression, thereby limiting cumulative exposure and its associated long-term risks.

The effective and safe application of Cladribine in either of its forms is not trivial. It demands from the clinician a deep understanding of its pharmacology, from its intracellular activation to its distinct pharmacokinetic profiles. It requires strict adherence to indication-specific protocols for dosing, administration, and handling. Most importantly, it necessitates a rigorous and comprehensive approach to risk management, including meticulous patient selection, mandatory pre-treatment screening for latent infections and malignancy risk, and vigilant monitoring of hematologic and organ function during and after therapy.

In conclusion, Cladribine is more than just a therapeutic agent; it is a clinical and regulatory case study. It represents a paradigm shift in the treatment of MS, establishing the viability of short-course immune reconstitution. In hematology, it remains a durable and effective standard of care. Decades after its initial synthesis, its full therapeutic potential continues to be explored in new indications like myasthenia gravis, underscoring its lasting importance. Future research aimed at identifying predictive biomarkers for both response and risk will be critical to further personalizing its use, ensuring that this powerful therapeutic tool can be applied with ever-increasing precision to the patients who stand to benefit most.

Works cited

1. Cladribine - Wikipedia, accessed July 24, 2025, https://en.wikipedia.org/wiki/Cladribine
2. Cladribine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 24, 2025, https://go.drugbank.com/drugs/DB00242
3. Cladribine (intravenous route) - Side effects & dosage - Mayo Clinic, accessed July 24, 2025, https://www.mayoclinic.org/drugs-supplements/cladribine-intravenous-route/description/drg-20062966
4. Cladribine (Mavenclad) - MS Society, accessed July 24, 2025, https://www.mssociety.org.uk/living-with-ms/treatments-and-therapies/disease-modifying-therapies/cladribine
5. Cladribine: Package Insert / Prescribing Information - Drugs.com, accessed July 24, 2025, https://www.drugs.com/pro/cladribine.html
6. Search Orphan Drug Designations and Approvals - FDA, accessed July 24, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=51690
7. Summary Review - accessdata.fda.gov, accessed July 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000SumR.pdf
8. Cladribine, accessed July 24, 2025, http://medbox.iiab.me/kiwix/wikipedia_en_medicine_2019-12/A/Cladribine
9. Mavenclad | European Medicines Agency (EMA), accessed July 24, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad
10. INDICATION and IMPORTANT SAFETY INFORMATION for MAVENCLAD® (cladribine) tablets, accessed July 24, 2025, https://www.mavenclad.com/en/hcp/important-safety-information.pdf
11. LEUSTATIN (cladribine) Injection For ... - accessdata.fda.gov, accessed July 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020229s034lbl.pdf
12. Oral Cladribine (Mavenclad®) for MS | Mellen Center Approach - Cleveland Clinic, accessed July 24, 2025, https://my.clevelandclinic.org/departments/neurological/depts/multiple-sclerosis/ms-approaches/oral-cladribine-mavenclad-ms
13. Cladribine | Apoptosis Inducer Compounds - R&D Systems, accessed July 24, 2025, https://www.rndsystems.com/products/cladribine_5292
14. [Cladribine (200 mg)] - CAS [4291-63-8] - USP Store, accessed July 24, 2025, https://store.usp.org/product/1134200
15. Cladribine | C10H12ClN5O3 | CID 20279 - PubChem, accessed July 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Cladribine
16. Definition of cladribine - NCI Drug Dictionary, accessed July 24, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cladribine
17. Cladribine (CAS 4291-63-8) - Cayman Chemical, accessed July 24, 2025, https://www.caymanchem.com/product/12085/cladribine
18. 3D structure for Cladribine (DB00242) | DrugBank Online, accessed July 24, 2025, https://go.drugbank.com/structures/small_molecule_drugs/DB00242
19. Cladribine | C10H12ClN5O3 - ChemSpider, accessed July 24, 2025, https://www.chemspider.com/Chemical-Structure.19105.html
20. CLADRIBINE - precisionFDA, accessed July 24, 2025, https://precision.fda.gov/ginas/app/ui/substances/c1e21f58-da88-455a-95b9-93572ab67dc7
21. Label: MAVENCLAD- cladribine tablet - DailyMed, accessed July 24, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c75e30a-a410-40f1-b653-04d532bd9144
22. 4291-63-8 | Cladribine - ChemScene, accessed July 24, 2025, https://www.chemscene.com/4291-63-8.html
23. The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis - PMC - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6373393/
24. Cladribine: Generic, MS Uses, Side Effects, Dosage - MedicineNet, accessed July 24, 2025, https://www.medicinenet.com/cladribine/article.htm
25. Leustat injection - Summary of Product Characteristics (SmPC) - (emc) | 13187, accessed July 24, 2025, https://www.medicines.org.uk/emc/product/13187/smpc
26. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review - PMC - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7708385/
27. MAVENCLAD Dosing, accessed July 24, 2025, https://www.mavenclad.com/en/home/taking-mavenclad/mavenclad-dosing.html
28. Dosing Overview - MAVENCLAD.com, accessed July 24, 2025, https://www.mavenclad.com/en/hcp/home/dosing-monitoring/dosing-monitoring.html
29. mavenclad - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf
30. Cladribine - Leustatin® - GlobalRPH, accessed July 24, 2025, https://globalrph.com/oncology/cladribine-leustatin/
31. Cladribine (oral route) - Side effects & dosage - Mayo Clinic, accessed July 24, 2025, https://www.mayoclinic.org/drugs-supplements/cladribine-oral-route/description/drg-20461358
32. MAVENCLAD.com, accessed July 24, 2025, https://www.mavenclad.com/en
33. mavenclad | ema, accessed July 24, 2025, https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf
34. Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials - PMC - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7311570/
35. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/24502830/
36. MAVENCLAD® (cladribine) Prescribing Information - EMD Serono, accessed July 24, 2025, https://www.emdserono.com/us-en/pi/mavenclad-pi.pdf
37. DOSING GUIDE - MAVENCLAD.com, accessed July 24, 2025, https://www.mavenclad.com/content/dam/web/healthcare/neurology/united-states/hcp/pdfs/04_22_US-MAV-01553_MAVENCLAD_Dosing_Guide.pdf
38. Mavenclad Dosage: Strength, Form, How to Take, and More - Healthline, accessed July 24, 2025, https://www.healthline.com/health/drugs/mavenclad-dosage
39. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis, accessed July 24, 2025, https://www.researchgate.net/publication/258338498_A_Placebo-Controlled_Trial_of_Oral_Cladribine_for_Relapsing_Multiple_Sclerosis
40. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/20089960/
41. Clinical Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Final Results from the 120-Week Phase IIIb Extension Trial to the CLARITY Study (P3.028) - Neurology.org, accessed July 24, 2025, https://www.neurology.org/doi/10.1212/WNL.86.16_supplement.P3.028
42. 2017-09-05 MMAVENCLAD™ CLARITY extension MS journal - Merck Group, accessed July 24, 2025, https://www.merckgroup.com/en/news/mavenclad-clarity-extension-ms-journal-05-09-2017.html
43. Safety and Efficacy of Oral Cladribine in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the 96 Week Phase IIIb Extension Trial to the CLARITY Study (P07.119), accessed July 24, 2025, https://www.neurology.org/doi/10.1212/WNL.80.7_supplement.P07.119
44. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study - ResearchGate, accessed July 24, 2025, https://www.researchgate.net/publication/320289888_The_efficacy_of_cladribine_tablets_in_CIS_patients_retrospectively_assigned_the_diagnosis_of_MS_using_modern_criteria_Results_from_the_ORACLE-MS_study
45. Cladribine tablets were associated with rapid onset of improvements in MRI outcomes in the ORACLE-MS trial (P3.2-061) - Neurology.org, accessed July 24, 2025, https://www.neurology.org/doi/10.1212/WNL.92.15_supplement.P3.2-061
46. Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials | MedPath, accessed July 24, 2025, https://trial.medpath.com/clinical-trial/08615cf860a7f5cd/euctr2019-000069-19-se-cladribine-tablets-multiple-sclerosis-treatment
47. Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS) | ClinicalTrials.gov, accessed July 24, 2025, https://clinicaltrials.gov/study/NCT03961204
48. Cladribine Use in Relapsing Multiple Sclerosis After 8–10 Years: Two Case Reports of Patients From the ORACLE-MS Study - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11681920/
49. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study - PubMed, accessed July 24, 2025, https://pubmed.ncbi.nlm.nih.gov/37012898/
50. CLARITY Extension Trial | MAVENCLAD® (cladribine) HCP Site, accessed July 24, 2025, https://imready.mavenclad.com/generic
51. 090 The effect of cladribine tablets on delaying the time to conversion to clinically definite multiple sclerosis (MS) or McDonald MS is consistent across subgroups in the ORACLE-MS study | Journal of Neurology, Neurosurgery & Psychiatry, accessed July 24, 2025, https://jnnp.bmj.com/content/90/e7/A29.1
52. LEUSTATIN® 1 mg/mL solution for infusion - NEW ZEALAND DATA SHEET, accessed July 24, 2025, https://www.medsafe.govt.nz/profs/datasheet/l/Leustatininf.pdf
53. LEUSTATIN Injection - NPS MedicineWise, accessed July 24, 2025, https://www.nps.org.au/medicine-finder/leustatin-solution-for-injection
54. Cladribine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 24, 2025, https://www.drugs.com/dosage/cladribine.html
55. Cladribine: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 24, 2025, https://www.rxlist.com/cladribine/generic-drug.htm
56. Mavenclad (cladribine) dosing, indications, interactions, adverse effects, and more, accessed July 24, 2025, https://reference.medscape.com/drug/mavenclad-cladribine-342213
57. Mavenclad: Dosing, contraindications, side effects, and pill pictures - epocrates online, accessed July 24, 2025, https://www.epocrates.com/online/drugs/8620/mavenclad
58. cladribine - LEUSTATIN Injection - E-lactancia, accessed July 24, 2025, https://e-lactancia.org/media/papers/Cladribina-DS-Janssen2018.pdf
59. INDICATION IMPORTANT SAFETY INFORMATION - MAVENCLAD.com, accessed July 24, 2025, https://www.mavenclad.com/content/dam/web/healthcare/neurology/united-states/pdfs/MAVENCLAD_HCP_ISI.pdf
60. Clinical Review(s) - accessdata.fda.gov, accessed July 24, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000MedR.pdf
61. Mavenclad (Cladribine Tablets): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 24, 2025, https://www.rxlist.com/mavenclad-drug.htm
62. Safety & Side Effects - MAVENCLAD.com, accessed July 24, 2025, https://www.mavenclad.com/en/home/why-mavenclad/safety-and-side-effects.html
63. MAVENCLAD 10 mg tablets - Summary of Product Characteristics (SmPC) - (emc) | 8435, accessed July 24, 2025, https://www.medicines.org.uk/emc/product/8435/smpc
64. Leustatin (Cladribine Injection For Intravenous Infusion Only): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 24, 2025, https://www.rxlist.com/leustatin-drug.htm
65. Leustatin Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 24, 2025, https://www.drugs.com/sfx/leustatin-side-effects.html
66. Leustatin - Cladribine Injection - Chemocare, accessed July 24, 2025, https://chemocare.com/druginfo/leustatin
67. Cladribine and Alcohol/Food Interactions - Drugs.com, accessed July 24, 2025, https://www.drugs.com/food-interactions/cladribine.html
68. Mavenclad (cladribine): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed July 24, 2025, https://www.webmd.com/drugs/2/drug-177053/mavenclad-4-tablet-pack-oral/details
69. Cladribine - StatPearls - NCBI Bookshelf, accessed July 24, 2025, https://www.ncbi.nlm.nih.gov/books/NBK545307/
70. FDA approves MAVENCLAD® (Cladribine) tablets, accessed July 24, 2025, https://www.mscare.org/fda-approves-mavenclad-cladribine-tablets/
71. Clinical Trials Using Cladribine - NCI, accessed July 24, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/cladribine
72. Clinical Trials in Hairy Cell Leukemia (HCL), accessed July 24, 2025, https://www.hairycellleukemia.org/clinicaltrials
73. Study Details | Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia, accessed July 24, 2025, https://www.clinicaltrials.gov/study/NCT00412594?term=RWJ-26251&rank=1
74. Study Details | Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | ClinicalTrials.gov, accessed July 24, 2025, https://clinicaltrials.gov/study/NCT00923013?term=AREA%5BNCTIdSearch%5D(NCT00412594%20OR%20NCT00923013%20OR%20NCT02131753)&rank=2
75. Merck KGaA, Darmstadt, Germany Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG) - EMD Serono, accessed July 24, 2025, https://www.emdserono.com/us-en/company/news/press-releases/oral-cladribine-in-generalized-myasthenia-gravis-29-08-2024.html
76. Cladribine Tablets After Treatment With Natalizumab (CLADRINA) - ClinicalTrials.gov, accessed July 24, 2025, https://www.clinicaltrials.gov/study/NCT04178005
77. Cladribine tablets in the new multiple sclerosis era - PMC - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12179467/
78. Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing–Remitting Multiple Sclerosis in Italy - PubMed Central, accessed July 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12255608/